Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 14/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14784825 | 0.87 | PTGER1 (0.41) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL13347873 | 0.86 | PTGER1 (0.55) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL4723254 | 0.86 | KDM1A (0.52) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL15076234 | 0.85 | CYP1A2 (0.42) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL18783694 | 0.85 | HTR2A (0.50) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL4720675 | 0.85 | MAPT (0.58) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL14784911 | 0.84 | PTGER1 (0.40) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL4722473 | 0.81 | PTGER1 (0.48) | KDM1APTGER1ALDH1A1MAPTTHRB | |
| SCHEMBL9967704 | 0.80 | KDM1A (0.56) | KDM1AALDH1A1MAPTGAACYP1A2 | |
| SCHEMBL18783949 | 0.79 | MAPT (0.58) | ALDH1A1MAPTGPR55HIF1ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-20100041590-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041590-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041590-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| EP-2099782-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074834-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074834-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041590-A1 | Compounds | SCD, SCD5, CYP11B2 | KDM1A 2650/4885PTGER1 928/4885ALDH1A1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.